Clearside Biomedical, Inc. (NASDAQ:CLSD – Get Rating) CEO George M. Lasezkay sold 20,030 shares of Clearside Biomedical stock in a transaction on Thursday, January 19th. The stock was sold at an average price of $1.46, for a total transaction of $29,243.80. Following the completion of the sale, the chief executive officer now owns 484,577 shares of the company’s stock, valued at approximately $707,482.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Clearside Biomedical Stock Performance
Shares of CLSD opened at $1.50 on Monday. Clearside Biomedical, Inc. has a 1 year low of $0.98 and a 1 year high of $2.85. The company has a market cap of $90.29 million, a price-to-earnings ratio of -18.75 and a beta of 1.83. The firm has a fifty day moving average of $1.27 and a 200-day moving average of $1.35.
Clearside Biomedical (NASDAQ:CLSD – Get Rating) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.17). Clearside Biomedical had a negative net margin of 17.15% and a negative return on equity of 16.13%. The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $16.50 million. Analysts predict that Clearside Biomedical, Inc. will post -0.52 EPS for the current year.
Wall Street Analysts Forecast Growth
Hedge Funds Weigh In On Clearside Biomedical
Several hedge funds and other institutional investors have recently modified their holdings of the company. Balyasny Asset Management LLC acquired a new stake in Clearside Biomedical in the third quarter worth about $25,000. Mackenzie Financial Corp acquired a new stake in Clearside Biomedical in the first quarter worth about $27,000. JPMorgan Chase & Co. lifted its holdings in Clearside Biomedical by 100.6% in the second quarter. JPMorgan Chase & Co. now owns 18,161 shares of the company’s stock worth $27,000 after purchasing an additional 9,109 shares during the period. Newman Dignan & Sheerar Inc. acquired a new stake in Clearside Biomedical in the third quarter worth about $31,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Clearside Biomedical by 34.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 67,170 shares of the company’s stock worth $76,000 after purchasing an additional 17,141 shares during the period. Institutional investors and hedge funds own 20.07% of the company’s stock.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc is a biopharmaceutical company, which delivers therapies to the back of the eye through the suprachoroidal space. Its pipeline include CLS-AX, Integrin Inhibitor, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F.
- Get a free copy of the StockNews.com research report on Clearside Biomedical (CLSD)
- CVS Health is Growing into an Integrated Healthcare Organization
- Is C3.ai Stock a ChatGPT Artificial Intelligence Play?
- NVIDIA Outlook Improving: Watchlist Candidate for 2023
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.